Quoin Pharmaceuticals, Ltd.
QNRX
$19.00
-$0.17-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 1.74M | 1.58M | 1.33M | 1.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.02M | 3.79M | 3.96M | 2.41M | 2.53M |
| Operating Income | -4.02M | -3.79M | -3.96M | -2.41M | -2.53M |
| Income Before Tax | -3.95M | -3.70M | -3.81M | -2.31M | -2.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.95M | -3.70M | -3.81M | -2.31M | -2.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.95M | -3.70M | -3.81M | -2.31M | -2.35M |
| EBIT | -4.02M | -3.79M | -3.96M | -2.41M | -2.53M |
| EBITDA | -3.99M | -3.77M | -3.93M | -2.38M | -2.50M |
| EPS Basic | -234.94 | -219.93 | -227.56 | -432.82 | -570.05 |
| Normalized Basic EPS | -4.20 | -3.93 | -4.06 | -7.73 | -10.18 |
| EPS Diluted | -235.20 | -220.50 | -227.56 | -434.36 | -575.75 |
| Normalized Diluted EPS | -4.20 | -3.93 | -4.06 | -7.73 | -10.18 |
| Average Basic Shares Outstanding | 588.20K | 588.20K | 586.30K | 186.90K | 144.30K |
| Average Diluted Shares Outstanding | 16.80K | 16.80K | 16.70K | 5.30K | 4.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |